Alnylam Pharmaceuticals (ALNY) — insider trading
Health Care · NASDAQ
Alnylam Pharmaceuticals (ALNY) has 44 reported SEC Form 4 insider transactions in our data, including 20 open-market sales among the most recent 44 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | SUPRAN BRYAN | Officer (EVP, CLO and Secretary) | Open-market sale | 1,758 | $226.88 | $398.9K | Form 4 |
| 2026-09-19 | Greenstreet Yvonne | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 107 | — | $0 | Form 4 |
| 2026-06-01 | Cravatt Benjamin | Director | Grant / award / vesting (derivative) | 4,393 | — | $0 | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Option exercise / conversion (derivative) | 3,830 | — | $0 | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 17 | $302.65 | $5.1K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 495 | $300.72 | $148.9K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 1,222 | $299.87 | $366.4K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 1,175 | $298.91 | $351.2K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Open-market sale | 921 | $297.71 | $274.2K | Form 4 |
| 2026-06-01 | PYOTT DAVID E I | Director | Option exercise / conversion | 3,830 | — | $0 | Form 4 |
| 2026-05-20 | Arbuckle Stuart A | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | Arbuckle Stuart A | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | Ausiello Dennis A | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | Ausiello Dennis A | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | HAMBURG MARGARET A | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | HAMBURG MARGARET A | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | KELLOGG PETER N | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | KELLOGG PETER N | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | PYOTT DAVID E I | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | PYOTT DAVID E I | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | Reitan Colleen F | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | Reitan Colleen F | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-20 | SCHULMAN AMY W | Director | Grant / award / vesting (derivative) | 1,802 | — | $0 | Form 4 |
| 2026-05-20 | SCHULMAN AMY W | Director | Grant / award / vesting | 838 | — | $0 | Form 4 |
| 2026-05-20 | Sigal Charles Elliott | Director | Grant / award / vesting (derivative) | 1,441 | — | $0 | Form 4 |
| 2026-05-20 | Sigal Charles Elliott | Director | Grant / award / vesting | 671 | — | $0 | Form 4 |
| 2026-05-13 | SCHULMAN AMY W | Director | Option exercise / conversion (derivative) | 11,250 | — | $0 | Form 4 |
| 2026-05-13 | SCHULMAN AMY W | Director | Option exercise / conversion | 11,250 | $70.20 | $789.8K | Form 4 |
| 2026-04-06 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 199 | $333.94 | $66.5K | Form 4 |
| 2026-04-06 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 293 | $331.89 | $97.2K | Form 4 |
| 2026-04-06 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 829 | $330.46 | $274.0K | Form 4 |
| 2026-04-06 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 909 | $329.76 | $299.8K | Form 4 |
| 2026-04-06 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 56 | $320.14 | $17.9K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 8 | $325.49 | $2.6K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 81 | $323.64 | $26.2K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 245 | $322.86 | $79.1K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 224 | $321.64 | $72.0K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 147 | $320.62 | $47.1K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 86 | $319.69 | $27.5K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 209 | $318.47 | $66.6K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 359 | $317.44 | $114.0K | Form 4 |
| 2026-04-02 | McLaughlin Melissa | Officer (Chief Human Resources Officer) | Open-market sale | 265 | $316.61 | $83.9K | Form 4 |
Ask the chat about ALNY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Alnylam Pharmaceuticals (ALNY).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.